An Extended Terminal Half-Life for Darbepoetin AlfaResults from a Single-Dose Pharmacokinetic Study in Patients with Chronic Kidney Disease not Receiving Dialysis

被引：0
|
作者：
Desmond Padhi
Liyun Ni
Blaire Cooke
Rafael Marino
Graham Jang
机构：
[1] Amgen Inc.,
来源：
Clinical Pharmacokinetics | 2006年 / 45卷
关键词：
Chronic Kidney Disease; Darbepoetin Alfa; Endogenous Erythropoietin; Single Subcutaneous Dose; Erythropoietic Agent;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：503 / 510
页数：7
相关论文
共 50 条
  • [11] Single centre experience of switching from standard half-life to extended half-life products in patients with severe haemophilia A and B
    Phillott, Anica
    Stanley, Jenna
    Alamelu, Jayanthi
    HAEMOPHILIA, 2018, 24 : 32 - 33
  • [12] EXTEND: AN OBSERVATIONAL COHORT STUDY OF EXTENDED DOSING WITH ARANESP® (DARBEPOETIN ALFA) IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS - INTERIM ANALYSIS
    Suranyi, M. G.
    Tolman, C.
    NEPHROLOGY, 2009, 14 : A50 - A51
  • [13] RESULTS OF A PROSPECTIVE REGISTRY STUDY OBSERVING THE SAFETY AND PATTERNS OF USE OF DARBEPOETIN ALFA IN EUROPEAN PAEDIATRIC CHRONIC KIDNEY DISEASE PATIENTS RECEIVING OR NOT RECEIVING DIALYSIS
    Schaefer, Franz
    Arbeiter, Klaus
    Hoppe, Bernd
    Jungraithmayr, Therese
    Klaus, Guenter
    Pape, Lars
    Dinavahi, Rajani
    Farouk, Mourad
    Manamley, Nick
    Vondrak, Karel
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 571 - 571
  • [14] Results Of A Prospective Registry Study Observing The Safety And Patterns Of Use Of Darbepoetin Alfa In European Paediatric Chronic Kidney Disease Patients Receiving Or Not Receiving Dialysis
    Schaefer, Franz
    Arbeiter, Klaus
    Hoppe, Bernd
    Jungraithmayr, Therese
    Klaus, Guenter
    Pape, Lars
    Dinavahi, Rajani
    Farouk, Mourad
    Martamley, Nick
    Vondrak, Karel
    PEDIATRIC NEPHROLOGY, 2014, 29 (09) : 1715 - 1716
  • [15] Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients
    Rakmanotham, Arunothai
    Moonla, Chatphatai
    Sosothikul, Darintr
    HAEMOPHILIA, 2023, 29 (01) : 156 - 164
  • [16] Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis - Author's reply
    Scott, SD
    PHARMACOTHERAPY, 2003, 23 (05): : 693 - 694
  • [17] Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products
    Tortella, Bartholomew J.
    Alvir, Jose
    McDonald, Margaret
    Spurden, Dean
    Fogarty, Patrick F.
    Chhabra, Amit
    Pleil, Andreas M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 643 - 653
  • [18] An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis
    Agarwal, A. K.
    Silver, M. R.
    Reed, J. E.
    Dhingra, R. K.
    Liu, W.
    Varma, N.
    Stehman-Breen, C.
    JOURNAL OF INTERNAL MEDICINE, 2006, 260 (06) : 577 - 585
  • [19] Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment
    Johnson, Franklin K.
    Wu, Shirley
    Schmith, Ginny
    Williams, Hadis
    Rutecki, Jasmine
    Halabi, Atef
    Feldkamp, Thorsten
    Sileno, Anthony
    PLOS ONE, 2024, 19 (12):
  • [20] Quality of Life of Patients with Advanced Chronic Kidney Disease Receiving Conservative Care without Dialysis
    Song, Mi-Kyung
    SEMINARS IN DIALYSIS, 2016, 29 (02) : 165 - 169
12345